Scinopharm Taiwan, Ltd. · TWSE:1789
Scinopharm Taiwan — Investor Presentation (February 2014)
23 slides from Scinopharm Taiwan's investor presentation, Feb 14, 2014
Slide 1: ScinoPharm Management Presentation
ScinoPharm Management Presentation TWSE 1789 February 14, 2014 1
Slide 2: Disclaimer
Disclaimer This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”). Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein.
Slide 3: Table of Content
Table of Content Overview of ScinoPharm Financial & Operating Results SPC Phase II Opening Video China Operations Update Business Outlook 3
Slide 4: Overview of ScinoPharm
Overview of ScinoPharm - An API + ANDA Company Active Pharmaceutical Ingredients Abbreviated New Drug Application 4
Slide 5: Background
Background Established in 1997 in Taiwan by founders from Syntex, listed on TWSE, current market cap ~ US$ 2.0 billion Major shareholders include Uni-President Group, Government’s Development Fund, Taiwan Sugar, etc. Facility & organization designed & built in Taiwan by experienced Syntex team
Slide 6: Business Overview
Business Overview Maintain dominant position in Specialty APIs for generic market. Strong customer base (320+) in US/EU/Japan, some through Indian generics. Aggressively developing Japan and China markets Developed ~70 generic APIs with 23 launched. Filed 47 DMFs in US (663 DMFs WW), leader in s
Slide 7: ScinoPharm - Oncological API Leader
ScinoPharm - Oncological API Leader Source: FDA 2013Q4 DMF database 7
Slide 8: World Class Facilities
World Class Facilities Taiwan (SPT) China (SPC) 6.6 hectares of land, 330K sq. ft. facilities 6.6 hectares of land with ~250M3 reactor with >200M3 reactor volume volume 8 of 18 production lines equipped with 2 of 8 production lines equipped with high potency capabilities for cytotoxics high
Slide 9: Financial & Operating Results
Financial & Operating Results 9
Slide 10: Cumulative P&L - Consolidated
Cumulative P&L - Consolidated 1Q~4Q,’13 1Q~4Q,’12 In NT$ million, except for EPS YoY (Unaudited) (Audited) Net Sales 5,088 4,573 11% Gross Profit 2,543 2,313 10% Gross margin 50% 51% Operating Expenses (1,145) (1,053) 9% Operating Income 1,398 1,260 11% Operating margin 27% 28% Other Rev.(Exp.) 11 1
Slide 11: Balance Sheet- Consolidated
Balance Sheet- Consolidated 2013/12/31 2012/12/31 In NT$ million (Unaudited) (Audited) Cash and Cash Equivalents 2,289 20% 3,035 29% Accounts Receivable 971 8% 841 8% Inventories 2,512 22% 1,870 18% Long-Term Investments 258 2% 168 2% Fixed Assets 4,214 37% 3,559 34% Total Assets 11,484 100% 10,340
Slide 12: Cash Flows- Consolidated
Cash Flows- Consolidated 1Q~4Q 2013 1Q~4Q 2012 In NT$ million (Unaudited) (Audited) Cash and cash equivalents at 3,035 3,294 beginning of period Cash flows from operating activities 945 980 CAPEX (1,225) (873) Long-term Investment (107) - Short-term borrowings 426 264 Cash Dividends (780) (631) Othe
Slide 13: Sales by Business
Sales by Business FY2012 FY2013 CMO CMO CRO 28% 2% 26% Generic Generic 72% 72% CRO <1% 13
Slide 14: Sales by Indications
Sales by Indications FY2012 FY2013 Others Others 11% 4% CNS Oncology CNS Oncology 39% 50% 39% 57% 14
Slide 15: Sales by Region
Sales by Region FY2012 FY2013 Rest of AU & NZ Rest of AU & NZ ROW ROW Asia Asia 5% <1% 5% 0% 12% India 7% India 10% 12% US & CAN US & CAN 51% 52% EU EU 27% 19% 15
Slide 16: China Operations Update
China Operations Update 16
Slide 17: Key Progress for China Market
Key Progress for China Market • Obtained drug production permits for 4 APIs ScinoPharm (3 for anti-cancer and 1for anti-viral) • Submitted 1 drug license application for an Changshu anti-cancer API • Submitted drug import license application for 9 ScinoPharm APIs (5 for anti-cancer, 2 for cardiovasc
Slide 18: SPC passed CRAM customer audits
SPC passed CRAM customer audits • ASLAN Pharmaceuticals and a multinational pharmaceutical company have been jointly developing an oncology compound • ScinoPharm Changshu has undertaken the API CRAM Services for this project and successfully passed the GMP audit by this customer • This targeted deli
Slide 19: Summary of SPC’s CRAMS projects
Summary of SPC’s CRAMS projects Product code Customer Indications Type Stage CN02-M006 Lee’s Pharma Ovarian Cancer API Phase III CN02-M002 Customer T Gastric disease API Phase II Prostate cancer, CN02-R006 Aslan JV API Phase II Breast caner CN02-M005 Customer I AIDS prevention API Phase II CN02-M007
Slide 20: Business Outlook
Business Outlook 20
Slide 21: 2014 Product Launch Plan
2014 Product Launch Plan Brand API Region Indications Regional Sales WW Sales Marketer MDS, Azacitidine US Celgene US$365MM* US$792 MM* Anti-cancer Dantrolene Malignant JHP Pharma- US US$22 MM* US$50 MM* (injectable) hyperthermia ceuticals MDS, AML Decitabine US Eisai US$254 MM* US$278 MM* Anti-canc
Slide 22: Outlook
Outlook Sustain Leadership in Oncological APIs Continue to launch and develop oncological injectable APIs & others with high technological barriers including Peptides Establish Presences in China Develop APIs and formulations to timely capture the generic business with strategic alliance and CRA
Slide 23: Brand Quality with Asian Advantages
Confidential Brand Quality with Asian Advantages www.scinopharm.com 23
ScinoPharm Taiwan — Investor Presentation (February 2014) on 6ix